UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Discover which indices swing the most and how those swings translate into trading opportunities, with practical tips to gauge momentum.
24,407 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Bitcoin has fallen from its peak and the chatter about a market dump intensifies. This guide breaks down three major ...
A major EV maker partners with Uber on a robotaxi plan, sending ripples through the market. This guide breaks down wh...
When a global intelligence stock sinking trend hits the market, it signals shifts in growth expectations and margins....
An in-depth look at Workhorse's path in 2026, focusing on earnings potential, drivers, and strategies for investors n...
Numbers matter, but stories move markets. This guide explains why narratives matter for stock prices and how investor...
A widely followed AI stock has cooled after a rapid rally, signaling risk for investors chasing gains. Here’s what to...
SpaceX could be the market's most talked-about IPO. This guide breaks down what to know, how to evaluate the opportun...
Iran’s envoy to China indicates Beijing could receive favorable terms in Hormuz transit, as Tehran coordinates with O...
A 55-year-old walks away with $1.2 million in his 401(K) only to risk losing access to the money before 59½ after a r...
Political headlines often ripple through markets and personal finances. This article breaks down what the bill clinto...
Small-cap growth has propelled some funds to the top this year. Discover the overlooked Vanguard outpacing this rally...